
The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal blood disorder.
The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal blood disorder.
© 2023 LBNN - All rights reserved.